Aligos Therapeutics (STU:5WK0) Short Interest


STU:5WK0 Aligos Therapeutics Inc STU:5WK0
26 GF Score
Price €5.14
GF Value €2.40
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Aligos Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:5WK0 vs SNTI, NTRB, CRVO: Short Interest Comparison

For the Biotechnology subindustry, Aligos Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aligos Therapeutics Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Aligos Therapeutics's Short Interest falls into.


STU:5WK0
26GF Score
Aligos Therapeutics Inc STU:5WK0
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aligos Therapeutics (STU:5WK0) Overvalued in 2026?

Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued. The current stock price of €5.14 is trading 114.2% above its estimated GF Value™ of €2.40. GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:5WK0:

  • Short Interest:
  • GF Value™: €2.40 vs. price of €5.14 (114.2% above fair value)
  • GF Score™: 26/100 with 4 warning signs

No single metric tells the full story. See the STU:5WK0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aligos Therapeutics Business Description

Other Exchanges ALGS:USA
Address One Corporate Drive, 2nd Floor, South San Francisco, CA, USA, 94080
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
26GF Score

Get the complete analysis for STU:5WK0

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.14
Price
€2.40
GF Value